PEPITEM: 5mg
Anti inflammatoryDescription
Pepitem (peptide inhibitor of trans-endothelial migration) is a 14-amino-acid endogenous peptide (sequence: svteqgaelsneer) produced by b lymphocytes in response to adiponectin signalling. first characterised in 2015 by researchers at the university of birmingham (nature medicine, pmid 25894827), it has since emerged as one of the better-supported molecular targets in inflammaging research — the study of how chronic, low-grade immune activity accumulates with age and drives degenerative disease. pepitem's primary mechanism is precise and selective: adiponectin binds receptors on b cells, triggering release of pepitem into circulation. pepitem then binds cadherin-15 on activated vascular endothelial cells, driving local sphingosine-1-phosphate (s1p) production, which signals crawling t lymphocytes to detach and stand down — physically blocking their migration across the vessel wall into tissue. critically, neutrophil and monocyte recruitment is unaffected. this selectivity for adaptive immune trafficking while leaving innate immunity intact is the defining distinction from broad immunosuppressants like corticosteroids. a 2024 npj aging study (doi:10.1038/s41514-024-00160-6) established the age-relevance: adiponectin receptor expression on b cells declines with age, reducing pepitem output and allowing progressive t-cell infiltration into metabolically active tissues. exogenous pepitem restored young-like leukocyte trafficking in aged mice. a separate bone pathway has also been characterised — pepitem acts on osteoblasts via ncam-1, promoting bone formation while suppressing resorption, producing dual anabolic and anti-catabolic effects in osteoporosis models. research spans rheumatoid arthritis, psoriatic arthritis, lupus, multiple sclerosis, psoriasis, and metabolic inflammation. a 2026 arthritis and rheumatology paper proposed pepitem replacement therapy as a targeted alternative to broad immunosuppression. as of july 2026, no human clinical trials have been registered or completed. for research and educational purposes only. not fda-approved. consult a qualified healthcare professional.
Specifications
| Amount in Vial | [needs review] |
|---|---|
| BAC Water | [needs review] |
| Amount per Unit | [needs review] |
| Recommended Dose | [needs review — no published human dosing data found] |
| Frequency | [needs review] |
| Injection Type | Subcutaneous |
| Timing | Store lyophilised at -20°C. Reconstitute per established protocol when available. Research compound — no established clinical administration schedule as of July 2026. |
Dose Calculator
Based on [needs review] (100-unit insulin syringe)
Quick Reference
Reconstitution
Vial size: [needs review]
Add BAC water: [needs review]
Concentration: [needs review]
For research and educational use only.
This page provides research dosing information only. Not intended as medical advice. Consult a qualified professional before any use.